Lupin tops most reputed pharma brand list

Image
Press Trust of India Mumbai
Last Updated : Aug 17 2016 | 6:48 PM IST
Domestic pharma majors Lupin, Sun Pharma and Cipla have dominated the list of top reputed pharmaceuticals brand survey released today.
City-based Lupin Pharmaceuticals tops in reputation leading the country's most reputed pharmaceutical brands' list, as per 'Top Most Reputed Pharmaceutical Brand' study conducted by BlueBytes in association with TRA Research.
Sun Pharmaceutical, with a 52 per cent Brand Rep Score and Cipla with 28 per cent bagged the second and third spots, followed by Dr Reddy's Laboratories at fourth.
Among global brands, GSK led the way, followed by Pfizer and Abbott. In all, 41 domestic and 17 international pharmaceutical brands were listed in the study.
"India's reputation as the largest producer of generic drugs in the world has become vulnerable in light of the changing patent regime in the country. Reports say that by 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size," said Pooja Kaura, chief spokesperson for India's Most Reputed Brands.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 17 2016 | 6:48 PM IST

Next Story